BURLINGTON, Mass., May 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three high-priced agents—Celgene/Taiho's Abraxane, Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals' Estybon and Merrimack Pharmaceuticals' MM-398 (a novel formulation of irinotecan). Even though these agents do not substantially improve the overall survival of pancreatic cancer patients, they will have a significant impact on current treatment.
The Pharmacor Pancreatic Cancer report also finds that significant commercial reward awaits developers of therapies that are more effective and better tolerated than the FOLFIRINOX regimen in this disease, as the need for efficacious, well-tolerated therapies will remain through 2022.
"There is a dire need for novel therapies to, at a minimum, match FOLFIRINOX's efficacy," said Decision Resources Analyst Orestis Mavroudis-Chocholis Ph.D. "FOLFIRINOX is reserved for young, fitter patients, who are better able to tolerate it, and is therefore prescribed to only a minority of pancreatic cancer patients who typically have rapidly progressing disease and declining performance status. Even an agent with equal efficacy but a better safety profile will quickly become the standard of care in pancreatic cancer."
The report also finds that physicians are excited by the prospect of SPARC stromal overexpression as a predictive biomarker for response to Abraxane and hope that this could signal the start of a personalized approach to the treatment of pancreatic cancer.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
|SOURCE Decision Resources|
Copyright©2012 PR Newswire.
All rights reserved